Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Atezolizumab for TNBC

Erika Hamilton • 2 Jun 2019
ASCO 2019
Breast Cancer General Atezolizumab

Erika Hamilton, MD, of the Sarah Cannon Research Institute, Nashville. TN, discusses the use of
atezolizumab for the treatment of triple-negative breast cancer (TNBC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Erika Hamilton

1:05
CAMBRIA 1: camizestrant ER+/HER2- early breast cancer
Erika Hamilton • 12 Dec 2023
2:03
The landscape of oral SERDs and their potential in ER+ breast cancer
Erika Hamilton • 12 Dec 2023
1:56
Vepdegestrant + palbociclib in ER+ metastatic breast cancer: Phase Ib trial results
Erika Hamilton • 12 Dec 2023
1:08
Non-adherence in breast cancer treatment
Erika Hamilton • 20 Oct 2023

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals